Biotech News

Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Aziyo Biologics (AZYO)Aziyo Biologics2026-06-25 13:46 ESTCompany update

GAITHERSBURG, Md., March 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it granted equity awards on March 10, 2026 to three new employees as inducement awards under the Elutia Inc.

Open original release

Related news

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

AZYOAziyo Biologics2026-06-25 13:46 EST

Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Regains Compliance with Nasdaq Listing Requirements

AZYOAziyo Biologics2026-06-25 13:46 EST

Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process

View all latest news

Aziyo Biologics

Aziyo Biologics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

AZYOAziyo Biologics2026-06-26 09:25 EST

Elutia to Present at Planet MicroCap Showcase 2026 on June 17th

AZYOAziyo Biologics2026-06-26 09:25 EST

Elutia Reports First Quarter 2026 Results and Highlights NXT-41x Progress Toward $1.5 Billion U.S. Plastic and Reconstructive Surgery Market

AZYOAziyo Biologics2026-06-26 09:25 EST

Elutia to Present at the 16th Annual LD Micro Invitational on May 18th

AZYOAziyo Biologics2026-06-26 09:25 EST

Elutia to Present at Global BioInnovation Forum on NXT-41x Biomatrix Program for Plastic and Reconstructive Surgery

AZYOAziyo Biologics2026-06-26 09:25 EST

Elutia Reports Preliminary Fourth Quarter 2025 Results, Strengthened Financial Position, and Upcoming NXT-41x Milestones

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States